Affiliation:
1. Department of Stomatology The Second Hospital of Tianjin medical university Tianjin 300211 China
2. School and Hospital of Stomatology Tianjin Medical University Tianjin 30070 China
3. Beijing Biosis Healing Biological Technology Co. Ltd. Beijing 102600 China
4. Department of Orthopaedics The Fourth Medical Centre Chinese PLA General Hospital Beijing 100048 China
Abstract
AbstractRestoring bone homeostasis is the key to the treatment of osteoporosis. How to increase osteogenic ability or inhibit osteoclast activity has always been a topic of great concern. In recent years, short peptides with biological activity have received great attention in bone repair. However, the application of short peptides is still limited due to the lack of a stable and targeted delivery system. Poly(lactic‐co‐glycolic acid) (PLGA) nanoparticles modified by alendronate (AL) to transport osteogenic peptides (OGP) (AL‐PLGA@P NPs) are designed. Benefiting from the high affinity of AL for hydroxyapatite, AL‐PLGA@P NPs have the ability to target bone. In this delivery system, OGP that promotes osteogenesis synergizes with AL, which inhibits osteoclasts, to regulate bone homeostasis, which gives them more advantages in the treatment of osteoporosis. The data shows that nanoparticles can selectively deliver peptides to the bone surface without systemic toxicity. Moreover, nanoparticles can upregulate osteogenesis‐related factors (ALP, Runx‐2, and BMP2) and downregulate osteoclast‐related factors (TRAP and CTSK) in vitro. With AL‐PLGA@P NPs, bone microarchitecture and bone mass are improved in ovariectomized osteoporosis rats. Therefore, this study proposes a novel osteoporosis‐based drug system that effectively improves bone density.
Funder
National Natural Science Foundation of China
Natural Science Foundation of Tianjin City
Subject
Pharmaceutical Science,Biomedical Engineering,Biomaterials
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献